Opportunity Information: Apply for RFA MH 11 021
Apply for RFA MH 11 021
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Viral and Host Genetic Factors Regulating HIV Associated CNS Disease (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Jul 29, 2010 and posted on Jul 29, 2010.
- Applicants must submit their applications by Jan 6, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Native American tribal governments (Federally recognized) State governments Public and State controlled institutions of higher education Private institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Small businesses County governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity "Viral and Host Genetic Factors Regulating HIV Associated CNS Disease (R21)" (RFA-MH-11-021) was a discretionary research grant program sponsored by the National Institute of Mental Health (NIMH) in partnership with the National Institute of Neurological Disorders and Stroke (NINDS). Its central goal was to stimulate exploratory and developmental research on why HIV-1 Associated Neurocognitive Disorders (HAND) continue to affect a large share of people living with HIV even in the era of highly active antiretroviral therapy (HAART). The announcement highlights that clinical studies were showing more than half of HIV-infected patients could exhibit HAND despite treatment, pointing to unresolved mechanisms in the brain and central nervous system (CNS) that are not fully addressed by standard antiviral suppression.
The scientific emphasis of the program was on identifying and understanding genetic factors from both the virus and the host that influence the development, progression, and clinical presentation of HAND, particularly in the context of treatment. A key theme was the interaction among three elements inside the CNS: (1) viral genetic variation, (2) host genetic variation, and (3) the effects of therapeutic drugs. The FOA encouraged applicants to pursue "novel genetic paradigms" that could explain how these interactions shape CNS pathology and neurocognitive outcomes, including why some individuals remain vulnerable to impairment while others do not.
To achieve these aims, the FOA explicitly encouraged the use of modern, high-throughput and integrative genetics and genomics approaches. Examples named in the announcement include transcriptomics, phenomics, epigenomics, whole-genome association studies (GWAS), next-generation sequencing, exome sequencing, and systems biology. It also stressed the importance of validation, meaning that discoveries should be tested and supported using appropriate experimental and translational platforms such as in vitro systems, animal models, and human samples. In practical terms, the program was designed to support studies that could move from discovery (finding candidate variants, pathways, or signatures) to early validation (showing biological relevance to HAND mechanisms in the CNS).
The funding mechanism was the NIH Exploratory/Developmental Grant (R21), which is commonly used for early-stage, higher-risk projects that can generate preliminary data and open up new lines of investigation. The FOA ran in parallel with a companion announcement of the same scientific scope using the R01 mechanism (MH-11-020), giving investigators a choice between an exploratory R21 pathway and a more extensive R01 pathway depending on project maturity and scale. The award ceiling listed for this R21 opportunity was $200,000, and the total estimated funding across the participating institutes was about $3,000,000 for the cycle referenced (approximately $2,000,000 from NIMH and $1,000,000 from NINDS in FY 2011). No cost sharing or matching was required.
Eligibility was broad and included many organization types that commonly apply for NIH research funding. Eligible applicants included public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities), for-profit organizations (including small businesses and other for-profits), state and local governments, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, independent school districts, and special district governments. The FOA also allowed a wide range of additional eligible applicants such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, faith-based and community-based organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations) as well as regional organizations and eligible federal agencies.
Administratively, the opportunity was posted July 29, 2010, with an original and final application due date of January 6, 2011, and it was archived February 6, 2011. The activity categories aligned with health research, and the CFDA listings included 93.242 (Mental Health Research Grants) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). The full announcement was hosted on the NIH grants website at the link provided in the notice.
FAQs: Viral and Host Genetic Factors Regulating HIV Associated CNS Disease (R21) (RFA-MH-11-021)
What is the name and identifier of this NIH funding opportunity?
The funding opportunity is titled "Viral and Host Genetic Factors Regulating HIV Associated CNS Disease (R21)" and carries the FOA number RFA-MH-11-021.
Which NIH institutes sponsored this opportunity?
This discretionary research grant program was sponsored by the National Institute of Mental Health (NIMH) in partnership with the National Institute of Neurological Disorders and Stroke (NINDS).
What is the main purpose of this FOA?
The central goal was to stimulate exploratory and developmental research to understand why HIV-1 Associated Neurocognitive Disorders (HAND) continue to affect a large share of people living with HIV, even in the era of highly active antiretroviral therapy (HAART).
Why does HAND remain a research focus even with HAART available?
The announcement noted that clinical studies were showing more than half of HIV-infected patients could exhibit HAND despite treatment, suggesting there are unresolved mechanisms in the brain and central nervous system (CNS) that are not fully addressed by standard antiviral suppression.
What scientific topic areas did the FOA emphasize?
The FOA emphasized identifying and understanding genetic factors from both the virus and the host that influence the development, progression, and clinical presentation of HAND, particularly in the context of treatment.
What key interaction did the FOA highlight within the CNS?
A central theme was the interaction among: (1) viral genetic variation, (2) host genetic variation, and (3) the effects of therapeutic drugs, and how these together shape CNS pathology and neurocognitive outcomes.
What kinds of research questions was the FOA trying to enable?
The FOA encouraged "novel genetic paradigms" to explain how viral genetics, host genetics, and therapeutic drug effects interact in the CNS, including why some individuals remain vulnerable to impairment while others do not.
What types of methods and technologies were encouraged?
The announcement explicitly encouraged modern, high-throughput, and integrative genetics and genomics approaches, including transcriptomics, phenomics, epigenomics, whole-genome association studies (GWAS), next-generation sequencing, exome sequencing, and systems biology.
Did the FOA expect studies to include validation?
Yes. The FOA stressed validation, meaning discoveries should be tested and supported using appropriate experimental and translational platforms such as in vitro systems, animal models, and human samples.
How did the FOA describe the intended research arc (discovery vs. validation)?
In practical terms, the program was designed to support work that could move from discovery (identifying candidate variants, pathways, or signatures) to early validation (showing biological relevance to HAND mechanisms in the CNS).
What grant mechanism was used?
This opportunity used the NIH Exploratory/Developmental Grant mechanism, R21, which is commonly used for early-stage, higher-risk projects intended to generate preliminary data and open new lines of investigation.
Was there a companion opportunity using a different mechanism?
Yes. The FOA ran in parallel with a companion announcement of the same scientific scope using the R01 mechanism (MH-11-020), allowing investigators to choose an exploratory R21 pathway or a more extensive R01 pathway depending on project maturity and scale.
What was the award ceiling for this R21 opportunity?
The award ceiling listed for this R21 opportunity was $200,000.
How much total funding was estimated for the cycle referenced?
The total estimated funding across the participating institutes was about $3,000,000 for the referenced cycle, with approximately $2,000,000 from NIMH and $1,000,000 from NINDS in FY 2011.
Was cost sharing or matching required?
No cost sharing or matching was required.
Who was eligible to apply?
Eligibility was broad and included public and private institutions of higher education; nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities); for-profit organizations (including small businesses and other for-profits); state and local governments; tribal governments and tribal organizations; public housing authorities/Indian housing authorities; independent school districts; and special district governments.
Were certain institution types explicitly noted as eligible?
Yes. The FOA also allowed additional eligible applicants such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, faith-based and community-based organizations, U.S. territories or possessions, non-U.S. entities (foreign organizations), regional organizations, eligible federal agencies, and other listed organization categories.
Were non-U.S. (foreign) organizations eligible?
Yes. The FOA indicated that non-U.S. entities (foreign organizations) were eligible applicants.
What were the key dates for this opportunity?
The opportunity was posted on July 29, 2010. The original and final application due date was January 6, 2011. The announcement was archived on February 6, 2011.
What general activity category did this opportunity fall under?
The activity categories aligned with health research.
What CFDA numbers were associated with this FOA?
The CFDA listings included 93.242 (Mental Health Research Grants) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants website at the link provided in the notice.
Is this FOA still active?
No. Based on the provided information, it was archived on February 6, 2011, and had a final application due date of January 6, 2011.
Browse more opportunities from the same category: Health
Next opportunity: C.A.S.T for Kids
Previous opportunity: Viral and Host Genetic Factors Regulating HIV Associated CNS Disease (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 11 021
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 11 021) also looked into and applied for these:
| Funding Opportunity |
|---|
| Biomedical Prevention of HIV Research Education (R25) Apply for RFA AI 10 027 Funding Number: RFA AI 10 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| State Planning and Establishment Grants for the Affordable Care Acts Exchanges Apply for IE HBE 10 001 Funding Number: IE HBE 10 001 Agency: CMS Consumer Information Insurance Oversight Category: Health Funding Amount: $1,000,000 |
| Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP HTM) (U19) Apply for RFA AI 10 006 Funding Number: RFA AI 10 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Expanded Social Marketing Project in Nigeria (ESMPIN) Apply for RFA OAA 620 10 016 Funding Number: RFA OAA 620 10 016 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| FY11 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Illinois, Chicago Area). Apply for PA FPH 11 003 Funding Number: PA FPH 11 003 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $402,181 |
| Nutrition and Alcohol Related Health Outcomes (R03) Apply for PA 10 240 Funding Number: PA 10 240 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| FY11 Announcement of Anticipated Availability of Funds for Family Planning Services Grants (Illinois, Chicago Area) Apply for PA FPH 11 003 011753 Funding Number: PA FPH 11 003 011753 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $402,181 |
| Epi Centers for the Prevention of Healthcare Associated Infections, Antimicrobial Resistance and Adverse Events (U54) Apply for RFA CI 11 001 Funding Number: RFA CI 11 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Structural Interventions, Alcohol Use, and Risk of HIV/AIDS (R21) Apply for PA 10 243 Funding Number: PA 10 243 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Structural Interventions, Alcohol Use, and Risk of HIV/AIDS (R01) Apply for PA 10 242 Funding Number: PA 10 242 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biobehavioral Research Awards for Innovative New Scientists (BRAINS) (R01) Apply for RFA MH 11 050 Funding Number: RFA MH 11 050 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Alcohol Induced Metabolic and Hepatic Injury (AIMHI) (R01) Apply for RFA AA 11 002 Funding Number: RFA AA 11 002 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Patient Protection and Affordable Care Act (Affordable Care Act) State Supplemental Funding for Healthy Communities, Tobacco Prevention and Control, Diabetes Prevention and Control, and Behavioral Risk Factor Surveillance System Apply for RFA DP09 90101SUPP10 Funding Number: RFA DP09 90101SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $50,000 |
| Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP HTM) Competitive Revisions (U19) Apply for RFA AI 10 007 Funding Number: RFA AI 10 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,400,000 |
| Mechanisms Mediating Changes in Central Regulation of Bone Mass (R01) Apply for RFA AG 11 006 Funding Number: RFA AG 11 006 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Planning Grant The Money Follows the Person Rebalancing Demonstration Program Apply for CMS 1LI 11 002 Funding Number: CMS 1LI 11 002 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $200,000 |
| Guidance for Supplemental Funding to Funding Opportunity Announcement (FOA) PS08 802, HIV/AIDS Surveillance Enhancing Laboratory Reporting Apply for CDC RFA PS08 8020302SUPP10 Funding Number: CDC RFA PS08 8020302SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Grants for Early Medical/Surgical Subspecialists Transition to Aging Research (R03) Apply for RFA AG 11 007 Funding Number: RFA AG 11 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Protection and Affordable Care Act (PPACA) Emerging Infections Program (EIP) Enhancing Epidemiology and Laboratory Capacity (U01) Apply for RFA CI 10 003 Funding Number: RFA CI 10 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $650,000 |
| EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC) BUILDING AND STRENGTHENING EPIDEMIOLOGY, LABORATORY AND HEALTH INFORMATION SYSTEMS CAPACITY IN STATE AND LOCAL HEALTH DEPARTMENTS Apply for CDC RFA CI10 1012 Funding Number: CDC RFA CI10 1012 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 11 021", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.